Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

CXCR4 is a cytokine receptor used by HIV during cell attachment and infection. Overexpressed in the cancer stem cells of more than 20 human neoplasias, CXCR4 is a convenient antitumoral drug target. T22 is a polyphemusin-derived peptide and an effective CXCR4 ligand. Its highly selective CXCR4 binding can be exploited as an agent for the cell-targeted delivery and internalization of associated antitumor drugs. Sharing chemical and structural traits with antimicrobial peptides (AMPs), the capability of T22 as an antibacterial agent remains unexplored. Here, we have detected T22-associated antimicrobial activity and biofilm formation inhibition over Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa, in a spectrum broader than the reference AMP GWH1. In contrast to GWH1, T22 shows neither cytotoxicity over mammalian cells nor hemolytic activity and is active when displayed on protein-only nanoparticles through genetic fusion. Under the pushing need for novel antimicrobial agents, the discovery of T22 as an AMP is particularly appealing, not only as its mere addition to the expanding catalogue of antibacterial drugs. The recognized clinical uses of T22 might allow its combined and multivalent application in complex clinical conditions, such as colorectal cancer, that might benefit from the synchronous destruction of cancer stem cells and local bacterial biofilms.
Original languageEnglish
Article number1922
Number of pages16
JournalPharmaceutics
Volume13
Issue number11
DOIs
Publication statusPublished - 13 Nov 2021

Fingerprint

Dive into the research topics of 'Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4'. Together they form a unique fingerprint.

Cite this